Skip to content

Relationship Between Serum Apolipoprotein Levels and Weight Loss in Patients Undergoing Sleeve Gastrectomy for Morbid Obesity

Relationship Between Serum Apolipoprotein Levels and Weight Loss in Patients Undergoing Sleeve Gastrectomy for Morbid Obesity

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07325916
Enrollment
76
Registered
2026-01-08
Start date
2025-04-09
Completion date
2026-04-27
Last updated
2026-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Morbid Obesity Requiring Bariatric Surgery

Keywords

morbid obesity, serum apolipoproteins, apolipoprotein AI, apolipoprotein AII, apolipoprotein B100, apolipoprotein CII, apolipoprotein CIII, apolipoprotein D, apolipoprotein E, apolipoprotein E4, apolipoprotein H, apolipoprotein J, apolipoprotein M, sleeve gastrectomy, bariatric surgery

Brief summary

The study looks at whether a specific protein in the blood, called apolipoprotein, can predict how much weight a person might lose after sleeve gastrectomy, a surgery for people with severe obesity. We want to find a specific level of this protein that shows which patients are most likely to lose weight successfully after surgery. By identifying this level, we hope to guide doctors in deciding who should have the surgery and who might do better with non-surgical weight loss methods.

Detailed description

The subject of our research is whether serum apolipoprotein levels can be a predictive value for weight loss in patients who will undergo sleeve gastrectomy due to morbid obesity. Our aim is to determine a cut-off value for patients who benefit most from bariatric surgery based on preoperative serum apolipoprotein levels. By including this value among the surgical indications, we plan to direct patients less likely to benefit from surgery to conservative approaches.

Interventions

PROCEDURELaparoscopic Sleeve Gastrectomy

Laparoscopic Sleeve Gastrectomy

Sponsors

Yigit DUZKOYLU
Lead SponsorOTHER_GOV

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* Patients aged 18 to 75 * International Classification of Diseases (ICD) code E66 diagnosis (obesity) * Patients who have given consent for sleeve gastrectomy * Patients who are suitable for general anesthesia

Exclusion criteria

* Patients who did not give consent to be included in the study * Patients who are scheduled for surgery other than sleeve gastrectomy

Design outcomes

Primary

MeasureTime frame
Change in body mass index at 8 months8 months after surgery

Secondary

MeasureTime frame
Change in lipid profile at 8 months8 months after surgery

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Aug 18, 2026